title: Intracellular free calcium in the neutrophils of maintenance haemodialysis patients.
abstract: Chronic renal failure has on occasion been referred to as a state of calcium toxicity. The aim of this study was to investigate the status of intracellular free Ca2+ in the neutrophils of chronic renal failure patients on maintenance haemodialysis treatment. Factors previously suggested to influence intracellular free Ca2+ were investigated including PTH levels, oxidative stress and recombinant human erythropoietin administration. The study involved 14 chronic renal failure patients on the haemodialysis programme of the Pretoria Academic hospital. Intracellular free Ca2+ and transmembrane Ca2+ fluxes were investigated by fluorescence spectrophotometry. Increases above control values were found in intracellular free Ca2+ (P-value 0.0242) and in the transmembrane Ca2+ flux upon fMLP stimulation (P-value 0.0002). The results showed significant differences in intracellular free Ca2+ between patients on rHuEPO and patients not on rHuEPO. The apparently rHuEPO-induced increase in intracellular free Ca2+ persisted in the presence of calcium channel blockers. No overt indications of oxidative stress could be detected by the antioxidant vitamin levels. It is concluded that factors other than those associated with uraemia, such as rHuEPO administration, might contribute to the often reported increase in intracellular free Ca2+ in these patients. Further studies to investigate the relationship between intracellular free Ca2+, rHuEPO and calcium channel blockers are suggested.
authors.affiliation: Department of Physiology, University of Pretoria, Pretoria, Gauteng, South Africa. akoorts@medic.up.ac.za
authors.forename: A M
authors.initials: AM
authors.lastname: Koorts
authors.forename: M C
authors.initials: MC
authors.lastname: Kruger
authors.forename: C D
authors.initials: CD
authors.lastname: Potgieter
authors.forename: M
authors.initials: M
authors.lastname: Viljoen
mesh_terms: D000293:Adolescent; D000328:Adult; D002118:Calcium / Q000378:metabolism*; D035061:Control Groups; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007425:Intracellular Membranes / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism*; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis; D013997:Time Factors
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D002118:Calcium